Aktuellt
SENASTE
Redeye continues to see a very compelling ling term investment case. Scibase's Q3 results were mixed with higher sales than expected and higher costs. We make minor adjustments to our estimates and leave our Base case unchanged at SEK 11 per share.
LÄS MER
